Premium
Frataxin or a mutant Fe‐S cluster scaffold protein with frataxin‐bypassing ability directly stimulates mitochondrial cysteine desulfurase by exposing substrate‐binding sites (578.4)
Author(s) -
Pandey Alok,
Pain Jayashree,
Yoon Heeyong,
Dancis Andrew,
Pain Debkumar
Publication year - 2014
Publication title -
the faseb journal
Language(s) - English
Resource type - Journals
SCImago Journal Rank - 1.709
H-Index - 277
eISSN - 1530-6860
pISSN - 0892-6638
DOI - 10.1096/fasebj.28.1_supplement.578.4
Subject(s) - frataxin , scaffold protein , cysteine , microbiology and biotechnology , iron–sulfur cluster , biochemistry , chemistry , biogenesis , allosteric regulation , mutant , iron binding proteins , biology , biophysics , enzyme , signal transduction , gene
Fe‐S cluster biogenesis in mitochondria is essential for cell survival. During the process, the cysteine desulfurase Nfs1 binds the substrate cysteine, removing sulfur from the substrate and forming a persulfide on the active site cysteine in a process requiring the accessory protein Isd11. The persulfide sulfur is then transferred to the Isu scaffold, where it combines with iron to form the Fe‐S cluster intermediate. Frataxin is implicated in the process, although it is unclear where and how. We find that yeast frataxin (Yfh1) directly and specifically stimulates cysteine binding to Nfs1 by exposing substrate‐binding sites. This novel function of frataxin does not require iron, Isu1 or Isd11. The subsequent persulfide formation is independent of frataxin but is strictly dependent on Isd11. Importantly, a point mutation in Isu1 is able to rescue Fe‐S cluster synthesis in yeast mitochondria lacking Yfh1. In agreement with this finding, the Isu1 suppressor is found to mimic the frataxin effects on Nfs1, explaining the bypassing activity. We propose that Nfs1 undergoes at least two conformational changes for optimum activity. One change is mediated by frataxin/Yfh1 interaction and promotes substrate binding. A second change is mediated by Isd11 and induces persulfide formation. Friedreich's ataxia is an incurable neurodegenerative disease associated with frataxin deficiency. A small molecule or an Isu1 suppressor mimic capable of exposing the “buried” cysteine‐binding sites of the cysteine desulfurase perhaps could be developed into a drug for treating the disease. Grant Funding Source : Supported by NIH grants RO1AG030504 to D.P. and R37DK053953 to A.D.